Several phase 3 clinical trials of first-line immune checkpoint inhibitors (ICIs) in non- HER2-positive or HER2-negative advanced or metastatic GC or GEJC have shown a superior objective response rate (ORR), PFS, and OS [3,4,5,6]. This evidence concerns the gene ERBB2 and gastric cancer.